Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

← catalyst calendar

NCT06332534 · readout ≤ 315 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

110estimated

Sites

Countries

Australia, Belgium, Brazil +15

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-08

actual

When the study began enrolling

Primary completion

Jun 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Dec 2034

estimated

The whole study's end, after follow-up

First posted

2024-03-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-24

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Crohn's Disease

Intervention

Drug: Upadacitinib — also filed as RINVOQ

Primary outcomes

what the primary-completion date above is the date OF

Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64

measured At Week 64

Achievement of endoscopic response at Week 64 in participants who achieved clinical response per PCDAI at Week 12.

measured At Week 64

Number of Participants with Adverse Events

measured Through Week 156

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed